Acute Respiratory Distress Syndrome Pipeline Assessment, 2023 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, and Growth Prospects | RS BioTherapeutics, AVM Biotech, Cynata

Posted on
by

Acute Respiratory Distress Syndrome Pipeline Assessment, 2023 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, and Growth Prospects | RS BioTherapeutics, AVM Biotech, Cynata
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Acute Respiratory Distress Syndrome pipeline constitutes 60+ key companies continuously working towards developing 60+ Acute Respiratory Distress Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Acute Respiratory Distress Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Acute Respiratory Distress Syndrome Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Respiratory Distress Syndrome Market.

 

Some of the key takeaways from the Acute Respiratory Distress Syndrome Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Acute Respiratory Distress Syndrome treatment therapies with a considerable amount of success over the years. 
  • Acute Respiratory Distress Syndrome companies working in the treatment market are RS BioTherapeutics, AVM Biotechnology, Cynata Therapeutics, Vasomune Therapeutics, Aqualung Therapeutics, and others, are developing therapies for the Acute Respiratory Distress Syndrome treatment 
  • Emerging Acute Respiratory Distress Syndrome therapies in the different phases of clinical trials are- RSBT-001, AVM0703, CYP 001, AV 001, ALT-100, and others are expected to have a significant impact on the Acute Respiratory Distress Syndrome market in the coming years.   
  • In July 2023, Aqualung Therapeutics has commenced PUERTA, which is a P2A clinical trial conducted across multiple centers. This study is designed as a randomized, double-blind, and placebo-controlled investigation to evaluate the safety and effectiveness of the eNAMPT targeting mAb ALT-100 in patients with moderate to severe ARDS/VILI. The plan involves the randomization of 90 eligible participants at a ratio of 2:1. These participants will be administered either a single dose of ALT-100 mAb or a placebo through IV infusion upon confirmation of the diagnosis of moderate to severe ARDS.
  • In January 2023, Aqualung Therapeutics has disclosed initial findings concerning ALT-100. The preliminary outcomes from the Phase 1a trial demonstrate the safety of ALT-100. Furthermore, these results provide sufficient evidence to establish the suitable doses for evaluation in patients diagnosed with moderate to severe ARDS.
  • In April 2022, The FDA has granted approval to Direct Biologics to progress with a significant Phase 3 clinical trial utilizing its investigative EV Drug ExoFlow for the treatment of Acute Respiratory Distress Syndrome (ARDS).
  • In January 2022, Veru announced that the FDA has granted fast-track designation to Sabizabulin for treating high-risk hospitalized COVID-19 patients prone to developing acute respiratory distress syndrome.

 

Acute Respiratory Distress Syndrome Overview

Low blood oxygen levels are a major symptom of the deadly lung disease known as acute respiratory distress syndrome (ARDS). Individuals with ARDS typically have underlying medical conditions or have suffered severe trauma. Surfactant degrades and fluid accumulates inside the lungs’ small air sacs in ARDS. A surfactant is a frothy material that maintains the lungs’ maximum expansion for respiration.

 

Get a Free Sample PDF Report to know more about Acute Respiratory Distress Syndrome Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-pipeline-insight

 

Emerging Acute Respiratory Distress Syndrome Drugs Under Different Phases of Clinical Development Include:

  • RSBT-001: RS BioTherapeutics
  • AVM0703: AVM Biotechnology
  • CYP 001: Cynata Therapeutics
  • AV 001: Vasomune Therapeutics
  • ALT-100: Aqualung Therapeutics

 

Acute Respiratory Distress Syndrome Route of Administration

Acute Respiratory Distress Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

 

Acute Respiratory Distress Syndrome Molecule Type

Acute Respiratory Distress Syndrome Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Acute Respiratory Distress Syndrome Pipeline Therapeutics Assessment

  • Acute Respiratory Distress Syndrome Assessment by Product Type
  • Acute Respiratory Distress Syndrome By Stage and Product Type
  • Acute Respiratory Distress Syndrome Assessment by Route of Administration
  • Acute Respiratory Distress Syndrome By Stage and Route of Administration
  • Acute Respiratory Distress Syndrome Assessment by Molecule Type
  • Acute Respiratory Distress Syndrome by Stage and Molecule Type

 

DelveInsight’s Acute Respiratory Distress Syndrome Report covers around 60+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Acute Respiratory Distress Syndrome product details are provided in the report. Download the Acute Respiratory Distress Syndrome pipeline report to learn more about the emerging Acute Respiratory Distress Syndrome therapies

 

Some of the key companies in the Acute Respiratory Distress Syndrome Therapeutics Market include:

Key companies developing therapies for Acute Respiratory Distress Syndrome are – Fisher & Paykel Healthcare Limited, NRx Pharmaceuticals, Inc., Faron Pharmaceuticals, BioMarck Pharmaceuticals, GE Healthcare, Hamilton Company, Athersys, United Therapeutics, Apeptico Forschung, HEALIOS K.K, Dragerwerk AG & Co. KGaA, ALung Technologies, Inc ( LivaNova PLC), and others.

 

Acute Respiratory Distress Syndrome Pipeline Analysis:

The Acute Respiratory Distress Syndrome pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Acute Respiratory Distress Syndrome with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Respiratory Distress Syndrome Treatment.
  • Acute Respiratory Distress Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Acute Respiratory Distress Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Respiratory Distress Syndrome market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Acute Respiratory Distress Syndrome drugs and therapies

 

Acute Respiratory Distress Syndrome Pipeline Market Drivers

  • Rising incidence of Acute Respiratory Distress Syndrome, the rising geriatric population are some of the important factors that are fueling the Acute Respiratory Distress Syndrome Market.

 

Acute Respiratory Distress Syndrome Pipeline Market Barriers

  • However, increasing Cost of Treatment Therapeutics, lack of Skilled Professionals and other factors are creating obstacles in the Acute Respiratory Distress Syndrome Market growth.

 

Scope of Acute Respiratory Distress Syndrome Pipeline Drug Insight    

  • Coverage: Global
  • Key Acute Respiratory Distress Syndrome Companies: RS BioTherapeutics, AVM Biotechnology, Cynata Therapeutics, Vasomune Therapeutics, Aqualung Therapeutics, and others
  • Key Acute Respiratory Distress Syndrome Therapies: RSBT-001, AVM0703, CYP 001, AV 001, ALT-100, and others
  • Acute Respiratory Distress Syndrome Therapeutic Assessment: Acute Respiratory Distress Syndrome current marketed and Acute Respiratory Distress Syndrome emerging therapies
  • Acute Respiratory Distress Syndrome Market Dynamics: Acute Respiratory Distress Syndrome market drivers and Acute Respiratory Distress Syndrome market barriers 

 

Request for Sample PDF Report for Acute Respiratory Distress Syndrome Pipeline Assessment and clinical trials

 

Table of Contents

1. Acute Respiratory Distress Syndrome Report Introduction

2. Acute Respiratory Distress Syndrome Executive Summary

3. Acute Respiratory Distress Syndrome Overview

4. Acute Respiratory Distress Syndrome- Analytical Perspective In-depth Commercial Assessment

5. Acute Respiratory Distress Syndrome Pipeline Therapeutics

6. Acute Respiratory Distress Syndrome Late Stage Products (Phase II/III)

7. Acute Respiratory Distress Syndrome Mid Stage Products (Phase II)

8. Acute Respiratory Distress Syndrome Early Stage Products (Phase I)

9. Acute Respiratory Distress Syndrome Preclinical Stage Products

10. Acute Respiratory Distress Syndrome Therapeutics Assessment

11. Acute Respiratory Distress Syndrome Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Acute Respiratory Distress Syndrome Key Companies

14. Acute Respiratory Distress Syndrome Key Products

15. Acute Respiratory Distress Syndrome Unmet Needs

16 . Acute Respiratory Distress Syndrome Market Drivers and Barriers

17. Acute Respiratory Distress Syndrome Future Perspectives and Conclusion

18. Acute Respiratory Distress Syndrome Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/